Skip to main content

Biogen says it will not give up on Alzheimer’s after failed trials

Biogen Inc. executives sought on Wednesday to ease investors’ concerns over the recent failure of one of the company’s investigational Alzheimer's drugs.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.